Track market-moving stories before they get noisy

Wednesday, 13 May 2026 04:01 PM

Topic: 

Earnings Revenue of $1.17 Billion, up 3.9% YoY as Reported and up 2.2% YoY in Constant Currency(1)

Expects Fiscal 2026 Revenue Growth Outlook of 2.6%-4.6% YoY as Reported

Reiterates Midpoint of Fiscal 2026 Revenue Growth Outlook in Constant Currency(1) while Tightening Expected Range to 2.0%-4.0% YoY

Announces Retirement of Long-Serving CFO and Appointment of Internal CFO Successor

Second Quarter Fiscal 2026 Highlights

(All comparisons are against same quarter of the prior year, unless otherwise stated)

Revenue of $1,172 million, up 3.9% as reported and up 2.2% in constant currency(1); revenue was above the midpoint of the $1,150-$1,190 million guidance range and includes a positive impact from foreign currency movements of approximately $2 million relative to our guidance assumptions

Revenue of $754 million in North America, up 2.2%; record revenue of $192 million in Europe, up 6.2%; revenue of $226 million in Rest of World, up 8.0% 

Managed services revenue of $759 million, equivalent to approximately 65% of total revenue and up 1.6% 

GAAP diluted EPS of $1.28, above the midpoint of the guidance range of $1.22-$1.30

Non-GAAP diluted EPS of $1.78, above the midpoint of the guidance range of $1.73-$1.79

GAAP operating income of $183 million; GAAP operating margin of 15.6%, down 190 basis points compared to last year’s second quarter and 230 basis points sequentially, mainly due to costs related to leadership transition as well as benefit from changes in certain acquisitions related liabilities measured at fair value in the first fiscal quarter

Non-GAAP operating income of $252 million; non-GAAP operating margin of 21.5%, up 20 basis points as compared to last year’s second fiscal quarter and down 10 basis points sequentially 

Free cash flow of $80 million, comprised of cash flow from operations of $102 million, including $17 million of restructuring payments, less $21 million in net capital expenditures(2); excluding restructuring payments, free cash flow was $97 million; reiterates full year fiscal 2026 free cash outlook of $710 million to $730 million, excluding restructuring payments

Repurchased $138 million of ordinary shares during the second fiscal quarter

Twelve-month backlog of $4.28 billion, up $30 million sequentially and up 2.6% 

Amdocs Limited (the “Company” or “Amdocs”) announced today that Tamar Rapaport-Dagim, Chief Financial Officer and Chief Operating Officer, has decided to retire from the Company following a distinguished career spanning over two decades. Tal Rozenfeld, currently General Manager Head of Finance, has been appointed Chief Financial Officer, effective June 1st, 2026. Tamar will continue to complete the transition process to help ensure a seamless handover of responsibilities.

(1) Revenue on a constant currency basis assumes exchange rates in the current period were unchanged from the prior period
(2)Please refer to the Selected Financial Metrics tables below (figures may not sum because of rounding)

JERSEY CITY, NJ / ACCESS Newswire / May 13, 2026 / Amdocs Limited (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today reported operating results for the three months ended March 31, 2026.

"I'm excited to be leading Amdocs forward in the agentic era, as our vision is to become the primary partner of choice to turn the agentic opportunity into reality for our customers. We believe Amdocs is uniquely positioned to lead due to our deep industry knowledge and telco domain expertise, engineering and innovation pedigree, mission critical systems transformation leadership and our outcome-based business model. To realize our vision, we are aiming to move towards an agentic and automated portfolio, tailor agentic customer roadmaps, leverage strategic partnerships, and internally transform the way we operate. While we are continuing to refine our strategy, we are already seeing initial commercial engagements with the launch of aOS- Amdocs' agentic operating system for telco.

We are building this strategy on our strong business foundations, as demonstrated by solid Q2 results which show healthy sales, strong customer relationships and consistent operating execution," said Shimie Hortig, president and chief executive officer of Amdocs Management Limited.

"Project delivery continued as a defining strength for Amdocs this quarter, as reflected by many production milestones achieved for AT&T, Vodafone Germany and other flagship customers worldwide. Profitability improved year-over-year, demonstrating our continued focus on operational excellence and automation, and we generated healthy free cash flow of which we returned more than 100% to shareholders though share repurchases and dividend payments," said Tamar Rapaport-Dagim, chief financial officer and chief operating officer of Amdocs Management Limited.

Hortig continued, "I'm pleased with our financial and operational progress for the fiscal year to date, and while we are closely monitoring macroeconomic developments and customer spending behavior in the current climate, we are on track to achieve our fiscal 2026 financial guidance."

Hortig concluded, "On behalf of the Board and the entire leadership team, I want to thank Tamar for her exceptional leadership, partnership and dedication over the past 22 years. Throughout her tenure, Tamar has played a critical role in strengthening our financial foundation, leading operational excellence, supporting our strategic growth and helping position the company for long-term success. We are deeply grateful for her many contributions and wish her the very best. We are very pleased to appoint Tal Rozenfeld as our next Chief Financial Officer. Tal brings deep financial expertise, strong operational and business knowledge and a proven track record of leadership. Tal has been an important part of our finance and leadership team, and we are confident he will play a key role in driving the next phase of Amdocs' growth and execution."

Revenue

(All comparisons are against same quarter as the prior year, unless otherwise stated )

In millions

Three months ended

March 31, 2026

Actual

Guidance

Revenue

$1,172

$ 1,150 - $1,190

Revenue Growth, as reported

3.9%

Revenue Growth, constant currency(1)

2.2%

Revenue for the second fiscal quarter of 2026 was above the midpoint of Amdocs' guidance and includes positive impact from foreign currency movement of $2 million compared to our guidance assumptions

Revenue for the second fiscal quarter includes a positive impact from foreign currency movements of $19 million relative to the second quarter of fiscal 2025 and a positive impact from foreign currency movements of $3 million relative to the first quarter of fiscal 2026

Net Income and Earnings Per Share

In thousands, except per share data

Three months ended

March 31,

2026

2025

GAAP Measures

Net Income

$138,772

$164,001

Net Income attributable to Amdocs Limited

$137,815

$163,243

Diluted earnings per share

$1.28

$1.45

Non-GAAP Measures

Non-GAAP Net Income

$192,501

$201,017

Non-GAAP Net Income attributable to Amdocs Limited

$191,544

$200,259

Non-GAAP Diluted earnings per share

$1.78

$1.78

Non-GAAP net income excludes amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition related liabilities measured at fair value, equity-based compensation expenses, restructuring charges, and other, net of related tax effects. For further details of the reconciliation of selected financial metrics from GAAP to Non-GAAP, please refer to the tables below

Capital Allocation & Liquidity

Quarterly Cash Dividend Program: On May 13, 2026, the Board approved the Company's next quarterly cash dividend payment at the rate of $0.569 per share, and set June 30, 2026 as the record date for determining the shareholders entitled to receive the dividend, which will be payable on July 31, 2026

Share Repurchase Activity: Repurchased $138 million of ordinary shares during the second quarter of fiscal 2026

Commercial Paper Program: In March 2026, the Company established a commercial paper program, supported by the Revolving Credit Facility under which it may issue unsecured commercial paper up to a total of $800 million outstanding at any time, with maturities of up to 397 days from the date of issue. The net proceeds from the issuance of commercial paper are expected to be used for general corporate purposes. As of March 31, 2026, there was no outstanding borrowing amount under the commercial paper program

Revolving Credit Facility: In March 2026, the Revolving Credit Facility was amended to increase the amount from $500 million to an aggregate amount of $800 million

Twelve-month Backlog

Twelve-month backlog was $4.28 billion at the end of the second quarter of fiscal 2026, up approximately 2.6% as compared to last year's second fiscal quarter. Twelve-month backlog includes anticipated revenue related to contracts, estimated revenue from managed services contracts, letters of intent, maintenance and estimated on-going support activities.

Third Quarter Fiscal Year 2026 Outlook

In millions, except per share data

Q3 - 2026

Revenue

$ 1,155-$1,195

GAAP Diluted earnings per share

$ 1.39-$1.47

Non-GAAP Diluted earnings per share

$ 1.81-$1.87

Third quarter revenue guidance assumes a negative $1 million sequential impact from foreign currency fluctuations as compared to the second quarter of fiscal 2026

GAAP diluted EPS guidance does not include the impact of future restructuring charges

Third quarter non-GAAP diluted EPS guidance excludes primarily equity-based compensation expense of approximately $0.22-$0.24 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately $0.16 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects

Full Year Fiscal 2026 Outlook

FY 2026 - Year-over -Year growth

Current guidance

Previous guidance

Revenue Growth, as reported

2.6%-4.6%

1.5%-5.5%

Revenue Growth, constant currency (1)

2.0%-4.0%

1.0%-5.0%

GAAP Diluted earnings per share

12.0%-15.0%

10.0%-17.0%

Non-GAAP Diluted earnings per share

5.0%-7.0%

4.0%-8.0%

FY 2026, in millions

Current guidance

Previous guidance

Free Cash Flow (2)

$ 710-$730

$ 710-$730

Full year fiscal 2026 revenue guidance incorporates an expected positive impact from foreign currency fluctuations of approximately 0.6% year-over-year compared with a positive impact of 0.5% year-over-year previously, and includes some inorganic contribution

GAAP diluted EPS guidance does not include the impact of future restructuring charges

Non-GAAP diluted earnings per share growth excludes primarily equity-based compensation expense of approximately $0.97-$1.01 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately $0.58 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects

Non-GAAP operating margin is anticipated to be within a range of 21.3% to 21.9% for the full year fiscal 2026

Non-GAAP operating margin is comprised of GAAP operating margin, excluding amortization of purchased intangible assets and other, equity-based compensation expense, restructuring charges, and changes in certain acquisitions related liabilities measured at fair value

Non-GAAP effective tax rate is anticipated to be within a range of 16% to 19% for the full year fiscal 2026

Reiterates full year fiscal 2026 free cash flow(2) of $710 million to $730 million, excluding payments related to restructuring charges; free cash flow(2) is comprised of cash flow from operations, less net capital expenditures

The forward-looking statements regarding our third fiscal quarter 2026 and full year fiscal 2026 guidance take into consideration the Company's current expectations regarding macroeconomic, geopolitical and industry specific risks and various uncertainties and certain assumptions, some of which we will discuss on our earnings conference call. However, we note that market dynamics continue to shift rapidly and we cannot predict all possible outcomes, including those resulting from certain geopolitical events, the current inflationary environment, changes to trade policies including tariffs and trade restrictions and the resulting impact on economic activities (as our outlook assumes current economic conditions do not deteriorate significantly due to trade policy or other macro factors), global or regional events, and the prevailing level of macro-economic, business and operational uncertainty, including customer spending behavior which have created, and continue to create, a significant amount of uncertainty, or from current and potential customer consolidation or their other strategic corporate activities. See "Forward-Looking Statements" below.

Conference Call and Earnings Webcast Presentation Details

Amdocs will host a conference call and earnings webcast presentation on May 13, 2026 at 5:00 p.m. Eastern Time to discuss the Company's second quarter of fiscal 2026 results. To participate in the call, please register here to receive the dial-in numbers and unique access PIN. The conference call and webcast will also be carried live on the Internet and may be accessed via the Amdocs website at https://investors.amdocs.com. Presentation slides will be available shortly before the webcast.

Non-GAAP Financial Measures
This release includes non-GAAP financial measures, including non-GAAP diluted earnings per share, free cash flow(2), revenue on a constant currency(1) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth. These other non-GAAP measures exclude the following items:

amortization of purchased intangible assets and other acquisition-related costs;

changes in certain acquisition-related liabilities measured at fair value;

restructuring and unusual charges or benefits;

equity-based compensation expense;

other; and

tax effects related to the above.

Free cash flow(2) equals cash generated by operating activities less net capital expenditures. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs' results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs' results of operations in conjunction with the corresponding GAAP measures.

Amdocs believes that the presentation of non-GAAP financial measures, including non-GAAP diluted earnings per share, free cash flow(2), revenue on a constant currency(1) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth when shown in conjunction with the corresponding GAAP measures, provides useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations, as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business.

For its internal budgeting process and in monitoring the results of the business, Amdocs' management uses financial statements that do not include amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition-related liabilities measured at fair value, restructuring and unusual charges or benefits, equity-based compensation expense, other and related tax effects. Amdocs' management also uses the foregoing non-GAAP financial measures, in addition to the corresponding GAAP measures, in reviewing the financial results of Amdocs. In addition, Amdocs believes that significant groups of investors exclude these items in reviewing its results and those of its competitors, because the amounts of the items between companies can vary greatly depending on the assumptions used by an individual company in determining the amounts of the items.

Amdocs further believes that, where the adjustments used in calculating non-GAAP diluted earnings per share are based on specific, identified amounts that impact different line items in the Consolidated Statements of Income (including cost of revenue, research and development, selling, general and administrative, operating income, interest and other expenses, net, income taxes and net income), it is useful to investors to understand how these specific line items in the Consolidated Statements of Income are affected by these adjustments. Please refer to the Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP tables below.

Supporting Resources

Keep up with Amdocs news by visiting the Company's website

Subscribe to Amdocs' RSS Feed and follow us on Twitter, Facebook, LinkedIn and YouTube

About Amdocs

Amdocs helps the world's leading communications and media companies deliver exceptional customer experiences through reliable, efficient, and secure operations at scale. We provide software products and services that embed intelligence into how work runs across business, IT, and network domains - delivering measurable outcomes in customer experience, network performance, cloud modernization, and revenue growth. With our talented people, and more than 40 years of experience running mission-critical systems around the globe, Amdocs runs billions of transactions daily. Our technology is relied on every day, connecting people worldwide and advancing a more inclusive, connected world. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ:DOX) and reported revenue of $4.53 billion in fiscal 2025. For more information, visit www.amdocs.com.

Forward-Looking Statements

This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' strategy, including with respect to artificial intelligence and agentic opportunities, growth, financial outlook, and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks, uncertainties, and other important factors that may cause future results to differ materially from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers, Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025, and our Form 6-K furnished for the first quarter of fiscal 2026 on February 17, 2026.

Contact:
Matthew Smith
Head of Investor Relations
Amdocs
314-212-8328
E-mail: [email protected]

AMDOCS LIMITED

Consolidated Statements of Income
(In thousands, except per share data)

Three months ended
March 31,

Six months ended
March 31,

2026

2025

2026

2025

Revenue

$

1,171,979

$

1,128,203

$

2,327,918

$

2,238,258

Operating expenses:

Cost of revenue

716,733

698,049

1,444,456

1,380,308

Research and development

87,001

81,796

168,979

166,129

Selling, general and administrative

153,677

134,625

267,398

256,712

Amortization of purchased intangible assets and other

21,308

15,998

35,842

31,757

Restructuring charges

10,405

-

21,706

6,783

989,124

930,468

1,938,381

1,841,689

Operating income

182,855

197,735

389,537

396,569

Interest and other expense, net

(5,963

)

(8,465

)

(17,228

)

(14,874

)

Income before income taxes

176,892

189,270

372,309

381,695

Income taxes

38,120

25,269

75,083

65,842

Net income

$

138,772

$

164,001

$

297,226

$

315,853

Net income attributable to noncontrolling interests

957

758

1,845

1,477

Net income attributable to Amdocs Limited

$

137,815

$

163,243

$

295,381

$

314,376

Basic earnings per share attributable to Amdocs Limited

$

1.29

$

1.46

$

2.75

$

2.80

Diluted earnings per share attributable to Amdocs Limited

$

1.28

$

1.45

$

2.74

$

2.78

Cash dividends declared per ordinary share

$

0.569

$

0.527

$

1.096

$

1.006

Basic weighted average number of shares outstanding

107,095

111,961

107,541

112,357

Diluted weighted average number of shares outstanding

107,472

112,514

107,997

112,981

AMDOCS LIMITED
Selected Financial Metrics
(In thousands, except per share data)

Three months ended
March 31,

Six months ended
March 31,

2026

2025

2026

2025

Revenue

$

1,171,979

$

1,128,203

$

2,327,918

$

2,238,258

Non-GAAP operating income

251,836

240,106

501,775

475,504

Non-GAAP net income

192,501

201,017

389,632

389,894

Non-GAAP net income attributable to Amdocs Limited

191,544

200,259

387,787

388,417

Non-GAAP diluted earnings per share

$

1.78

$

1.78

$

3.59

$

3.44

Diluted weighted average number of shares outstanding

107,472

112,514

107,997

112,981

Free Cash Flows
(In thousands)

Three months ended
March 31,

Six months ended
March 31,

2026

2025

2026

2025

Net Cash Provided by Operating Activities

$

101,584

$

172,458

$

321,766

$

278,013

Purchases of property and equipment, net (a)

(21,237

)

(15,964

)

(53,476

)

(43,319

)

Free Cash Flow

$

80,347

$

156,494

$

268,290

$

234,694

(a) The amounts under "Purchase of property and equipment, net", include immaterial proceeds from sale of property and equipment for the three and six months ended March 31, 2026 and 2025, respectively.

AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands)

Three Months Ended March 31, 2026

GAAP

Amortization
of purchased intangible assets and other

Equity based compensation
expense

Changes in certain acquisitions
related liabilities measured at fair value

Restructuring charges

Other

Tax
effect

Non-GAAP

Operating expenses:

Cost of revenue

$

716,733

$

-

$

(11,392

)

$

(135

)

$

-

$

-

$

-

$

705,206

Research and development

87,001

(2,068

)

84,933

Selling, general and administrative

153,677

(24,539

)

866

130,004

Amortization of purchased intangible assets and other

21,308

(21,308

)

-

Restructuring charges

10,405

(10,405

)

-

Total operating expenses

989,124

(21,308

)

(37,999

)

731

(10,405

)

-

-

920,143

Operating income

182,855

21,308

37,999

(731

)

10,405

251,836

Interest and other expense, net

(5,963

)

(7,637

)

(13,600

)

Income taxes

38,120

7,615

45,735

Net income

138,772

21,308

37,999

(731

)

10,405

(7,637

)

(7,615

)

192,501

Net income attributable to noncontrolling interests

957

957

Net income attributable to Amdocs Limited

$

137,815

$

21,308

$

37,999

$

(731

)

$

10,405

$

(7,637

)

$

(7,615

)

$

191,544

Three Months Ended March 31, 2025

GAAP

Amortization
of purchased intangible assets and other

Equity based compensation
expense

Changes in certain acquisitions
related liabilities measured at fair value

Other

Tax
effect

Non-GAAP

Operating expenses:

Cost of revenue

$

698,049

$

-

$

(12,356

)

$

(360

)

$

-

$

-

$

685,333

Research and development

81,796

(2,283

)

79,513

Selling, general and administrative

134,625

(11,014

)

(360

)

123,251

Amortization of purchased intangible assets and other

15,998

(15,998

)

-

Restructuring charges

-

-

Total operating expenses

930,468

(15,998

)

(25,653

)

(720

)

-

-

888,097

Operating income

197,735

15,998

25,653

720

240,106

Interest and other expense, net

(8,465

)

(69

)

(8,534

)

Income taxes

25,269

5,286

30,555

Net income

164,001

15,998

25,653

720

(69

)

(5,286

)

201,017

Net income attributable to noncontrolling interests

758

758

Net income attributable to Amdocs Limited

$

163,243

$

15,998

$

25,653

$

720

$

(69

)

$

(5,286

)

$

200,259

AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands)

Six Months Ended March 31, 2026

GAAP

Amortization
of purchased intangible assets and other

Equity based
compensation
expense

Changes in certain acquisitions
related liabilities measured at fair value

Restructuring
charges

Other

Tax
effect

Non-GAAP

Operating expenses:

Cost of revenue

$

1,444,456

$

-

$

(22,765

)

$

(494

)

$

-

$

-

$

-

$

1,421,197

Research and development

168,979

(3,927

)

165,052

Selling, general and administrative

267,398

(35,397

)

7,893

239,894

Amortization of purchased intangible assets and other

35,842

(35,842

)

-

Restructuring charges

21,706

(21,706

)

-

Total operating expenses

1,938,381

(35,842

)

(62,089

)

7,399

(21,706

)

-

-

1,826,143

Operating income

389,537

35,842

62,089

(7,399

)

21,706

501,775

Interest and other expense, net

(17,228

)

(6,064

)

(23,292

)

Income taxes

75,083

13,768

88,851

Net income

297,226

35,842

62,089

(7,399

)

21,706

(6,064

)

(13,768

)

389,632

Net income attributable to noncontrolling interests

1,845

1,845

Net income attributable to Amdocs Limited

$

295,381

$

35,842

$

62,089

$

(7,399

)

$

21,706

$

(6,064

)

$

(13,768

)

$

387,787

Six Months Ended March 31, 2025

GAAP

Amortization
of purchased intangible assets and other

Equity based
compensation
expense

Changes in certain acquisitions
related liabilities measured at fair value

Restructuring
charges

Other

Tax
effect

Non-GAAP

Operating expenses:

Cost of revenue

$

1,380,308

$

-

$

(25,606

)

$

(360

)

$

-

$

-

$

-

$

1,354,342

Research and development

166,129

(4,554

)

161,575

Selling, general and administrative

256,712

(22,013

)

12,138

246,837

Amortization of purchased intangible assets and other

31,757

(31,757

)

-

Restructuring charges

6,783

(6,783

)

-

Total operating expenses

1,841,689

(31,757

)

(52,173

)

11,778

(6,783

)

-

-

1,762,754

Operating income

396,569

31,757

52,173

(11,778

)

6,783

475,504

Interest and other expense, net

(14,874

)

5,979

(8,895

)

Income taxes

65,842

10,873

76,715

Net income

315,853

31,757

52,173

(11,778

)

6,783

5,979

(10,873

)

389,894

Net income attributable to noncontrolling interests

1,477

1,477

Net income attributable to Amdocs Limited

$

314,376

$

31,757

$

52,173

$

(11,778

)

$

6,783

$

5,979

$

(10,873

)

$

388,417

AMDOCS LIMITED
Condensed Consolidated Balance Sheets
(In thousands)

As of

March 31,
2026

September 30,
2025

ASSETS

Current assets:

Cash and cash equivalents

$

214,495

$

324,999

Accounts receivable, net, including unbilled

938,182

935,751

Prepaid expenses and other current assets

364,347

331,387

Total current assets

1,517,024

1,592,137

Property and equipment, net

738,836

768,557

Lease assets

179,580

182,088

Goodwill and other intangible assets, net

3,243,895

3,046,962

Other noncurrent assets

684,535

660,086

Total assets

$

6,363,870

$

6,249,830

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities

Accounts payable, accruals and other

$

1,108,842

$

1,201,206

Short-term financing arrangements

250,000

-

Lease liabilities

36,017

38,725

Deferred revenue

152,434

118,861

Total current liabilities

1,547,293

1,358,792

Lease liabilities

134,567

140,776

Long-term debt, net of unamortized debt issuance costs

647,211

646,901

Other noncurrent liabilities

611,376

632,681

Total Amdocs Limited Shareholders' equity

3,382,292

3,429,453

Noncontrolling interests

41,131

41,227

Total equity

3,423,423

3,470,680

Total liabilities and equity

$

6,363,870

$

6,249,830

AMDOCS LIMITED
Consolidated Statements of Cash Flows
(In thousands)

Six months ended
March 31,

2026

2025

Cash Flow from Operating Activities:

Net income

$

297,226

$

315,853

Reconciliation of net income to net cash provided by operating activities:

Depreciation, amortization and impairment

103,747

94,460

Amortization of debt issuance cost

310

300

Equity-based compensation expense

62,089

52,173

Deferred income taxes

24,148

2,296

Loss from short-term interest-bearing investments

-

1,739

Net changes in operating assets and liabilities, net of amounts acquired:

Accounts receivable, net

(46,640

)

33,174

Prepaid expenses and other current assets

(23,114

)

(32,526

)

Other noncurrent assets

18,492

5,141

Lease assets and liabilities, net

(6,408

)

(1,194

)

Accounts payable, accrued expenses and accrued personnel

(90,120

)

(126,700

)

Deferred revenue

23,505

27,846

Income taxes payable, net

(5,003

)

(11,082

)

Other noncurrent liabilities

(36,466

)

(83,467

)

Net cash provided by operating activities

$

321,766

$

278,013

Cash Flow from Investing Activities:

Purchase of property and equipment, net (a)

(53,476

)

(43,319

)

Proceeds from sale of short-term interest-bearing investments

-

92,955

Net cash paid for business and intangible assets acquisitions

(217,663

)

(57,169

)

Net cash from equity investments and other

11,848

16,741

Net cash (used) provided by investing activities

$

(259,291

)

$

9,208

Cash Flow from Financing Activities:

Repurchase of shares

(284,513

)

(279,720

)

Proceeds from employee stock option exercises

3,193

11,422

Payments of dividends

(113,849

)

(107,810

)

Distribution to noncontrolling interests

(1,941

)

(2,209

)

Borrowings under financing arrangements

250,000

-

Payment of contingent consideration and deferred payment of business acquisitions

(25,869

)

(7,599

)

Net cash used in financing activities

$

(172,979

)

$

(385,916

)

Net decrease in cash and cash equivalents

(110,504

)

(98,695

)

Cash and cash equivalents at beginning of period

324,999

346,085

Cash and cash equivalents at end of period

$

214,495

$

247,390

AMDOCS LIMITED
Supplementary Information
(In millions)

Three months ended

March 31,

December 31,

September 30,

June 30,

March 31,

2026

2025

2025

2025

2025

North America

$

754.3

$

764.7

$

762.4

$

745.4

$

738.3

Europe

191.8

181.7

179.8

189.4

180.7

Rest of the World

225.8

209.5

208.0

209.6

209.2

Total Revenue

$

1,172.0

$

1,155.9

$

1,150.2

$

1,144.4

$

1,128.2

Three months ended

March 31,

December 31,

September 30,

June 30,

March 31,

2026

2025

2025

2025

2025

Managed Services Revenue

$

758.7

$

745.9

$

748.3

$

771.5

$

747.1

as of

March 31,

December 31,

September 30,

June 30,

March 31,

2026

2025

2025

2025

2025

12-Month Backlog

$

4,280

$

4,250

$

4,190

$

4,150

$

4,170

SOURCE: Amdocs - IR

The inventory modernization will enhance operational efficiency and accelerate network planning, rollout, and assurance for Vodafone Ireland, ensuring future readiness while aligning with the broader strategic objectives of the Vodafone Group

JERSEY CITY, NJ / ACCESS Newswire / May 13, 2026 / Amdocs (NASDAQ:DOX), a leading provider of software and services for communications and media companies, announced today that Vodafone Ireland has successfully gone live with Amdocs' latest Network Inventory solution as part of its initiative to modernize, harmonize, and evolve its network operations. This collaboration has replaced Vodafone Ireland's legacy system with the latest version of the Amdocs Network Inventory, empowering the Irish service provider to accelerate and automate the planning, deployment, and assurance of its mobile network and drive operational efficiency across the organization.

Amdocs Network Inventory, a cornerstone in enabling agile and autonomous networks, will serve as the foundation for harmonizing Vodafone Ireland's inventory models and processes with those of other Vodafone Group countries across Europe. By standardizing and streamlining systems and best practices, Vodafone Ireland aims to reduce the total cost of ownership, streamline operations, and deliver an enhanced user experience powered by automation, federation, and an intuitive user interface.

Leveraging a proven ‘develop-once-deploy-many' co-designed framework, Amdocs successfully delivered a high-impact project, harmonizing network operations and topology, in alignment with Vodafone Group's strategic network vision. In close collaboration with Vodafone Ireland and Vodafone Group teams, Amdocs modernized the existing inventory platform, executing a complex data migration and cleansing initiative with exceptional speed and precision.

This milestone reflects the strength of the partnership between Amdocs and Vodafone, as well as Amdocs' commitment to driving innovation and operational excellence across Vodafone's global network footprint.

"By moving to Amdocs' modern network inventory solution, we are strengthening our ability to plan, build, and manage our network more efficiently," said Sheila Kavanagh, Chief Network Officer at Vodafone Ireland. "This upgrade not only helps us deliver better service to our customers today, but also ensures we're well-prepared for tomorrow's connectivity demands."

"With service providers worldwide increasingly focused on autonomous networks, we're delighted to continue our collaboration with Vodafone Ireland as they progress through their network transformation journey," said Anthony Goonetilleke, Group President of Technology and Head of Strategy at Amdocs. "This go-live marks a key milestone in Vodafone's broader digital evolution, enabling greater automation, faster time to market, and seamless integration across group operations."

Supporting Resources

Learn more about Amdocs Network Inventory, here

Keep up with Amdocs news by visiting the company's website

Follow us on X, Facebook, LinkedIn, and YouTube

About Amdocs

Amdocs helps the world's leading communications and media companies deliver exceptional customer experiences through reliable, efficient, and secure operations at scale. We provide software products and services that embed intelligence into how work runs across business, IT, and network domains - delivering measurable outcomes in customer experience, network performance, cloud modernization, and revenue growth. With our talented people, and more than 40 years of experience running mission-critical systems around the globe, Amdocs runs billions of transactions daily. Our technology is relied on every day, connecting people worldwide and advancing a more inclusive, connected world. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ:DOX) and reported revenue of $4.53 billion in fiscal 2025. For more information, visit www.amdocs.com.

Amdocs' Forward-Looking Statement

This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025, and for the first quarter of fiscal 2026 on February 17, 2026.

Media Contacts

Mario Hajiloizi
Amdocs Public Relations
E-mail: [email protected]

SOURCE: Amdocs Management Limited

The agents, built using Google's AI models, enable enterprise-scale deployment of agentic AI across telecom workflows

JERSEY CITY, NJ / ACCESS Newswire / May 13, 2026 / Amdocs (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today announced the availability of Amdocs Telco Agents for Customer Experience in the Google Gemini Enterprise Agent Marketplace, Google Cloud's platform for building and deploying enterprise-grade AI agents.

These agents are now featured as part of Google Cloud's partner-built agents ecosystem in Gemini Enterprise, as announced at Google Cloud Next 2026, underscoring Amdocs' role in shaping the next wave of enterprise AI innovation. Built on Google Cloud's Gemini Enterprise platform, Amdocs Telco Agents for Customer Experience enable communications service providers (CSPs) to automate key customer-facing and operational processes, including customer care interactions, service request handling, issue resolution, and order orchestration.

The agents can reason, orchestrate, and execute end‑to‑end telco processes, improving resolution speed, cost efficiency, and customer satisfaction across digital and contact center channels. Built on aOS, Amdocs' agentic operating system for telcos, the solution combines Amdocs' Cognitive Core with Gemini Enterprise for CX to coordinate workflows across existing BSS/OSS systems and AI ecosystems. As the intelligence layer within aOS, Amdocs Cognitive Core applies telco-specific reasoning and governance to support scalable AI deployment within live telecom operations.

"Enterprise customers need AI solutions that are not only powerful but also secure, scalable, and easy to deploy," said Satish Thomas, Vice President, Applied AI & Platform Ecosystem, Google Cloud. "This collaboration brings together Google Cloud's cutting-edge AI capabilities with Amdocs' proven industry expertise, offering communications service providers an accelerated path to deploying agentic AI at scale."

"We're thrilled to be among a strategic group of companies globally to publish agents on Gemini Enterprise. This reinforces our agentic AI strategy to help CSPs move beyond traditional AI assistants toward autonomous systems that can execute complex service workflows end-to-end," said Anthony Goonetilleke, Group President of Technology and Head of Strategy at Amdocs. "By combining Amdocs' telecom expertise with Google Cloud's AI, these agents reduce handling time, improve first call resolution, and enable proactive issue prevention, while maintaining enterprise-grade trust, governance, and security."

Supporting Resources

Read more about aOS, here

Keep up with Amdocs news by visiting the company's website

Follow us on X, Facebook, LinkedIn, and YouTube

About Amdocs

Amdocs helps the world's leading communications and media companies deliver exceptional customer experiences through reliable, efficient, and secure operations at scale. We provide software products and services that embed intelligence into how work runs across business, IT, and network domains - delivering measurable outcomes in customer experience, network performance, cloud modernization, and revenue growth. With our talented people, and more than 40 years of experience running mission-critical systems around the globe, Amdocs runs billions of transactions daily. Our technology is relied on every day, connecting people worldwide and advancing a more inclusive, connected world. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ: DOX) and reported revenue of $4.53 billion in fiscal 2025. For more information, visit www.amdocs.com.

Amdocs' Forward-Looking Statement

This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025, and for the first quarter of fiscal 2026 on February 17, 2026.

Media Contacts

Swati Sharma
Amdocs Public Relations
E-mail: [email protected]

SOURCE: Amdocs Management Limited

Supporting 12,000 transactions per second across three active cloud regions, the Amdocs Entitlement Server sets a new benchmark on Microsoft Azure for performance, reliability, and availability needed by large telecom operators to confidently launch and sustain eSIM services at scale

JERSEY CITY, NJ / ACCESS Newswire / May 13, 2026 / Amdocs (NASDAQ:DOX), a leading provider of software and services for communications and media companies, today announced that its Entitlement Server, the core of the Amdocs eSIM Cloud, has achieved a sustained 12,000 Transactions Per Second (TPS) across three geographically distributed Microsoft Azure regions in a production-grade, active-active deployment. This milestone represents one of the highest publicly benchmarked throughput levels for a carrier-grade entitlement server.

Achieved in collaboration with Microsoft and aligned with Azure's Well-Architected Framework, the benchmark demonstrates the platform's ability to deliver sub-second latency, continuous availability, and resilience at scale, even during peak demand events such as device launches, mass eSIM activations, and nationwide Rich Communication Services (RCS) rollouts.

As the entitlement server evolves into a strategic control point between devices, networks, and digital services, performance and resilience have become critical differentiators. Industry recognition reflects this shift, with Counterpoint Research naming Amdocs the #1 Pacesetter in both the 2025 Entitlement Server and eSIM Orchestration rankings.

This benchmark highlights a new standard for evaluating entitlement platforms: sustained throughput and multi-region resilience under real production load. As eSIM adoption accelerates across smartphones, wearables, vehicles, and IoT, operators require platforms that can scale to billions of transactions without compromise.

Built as a cloud-based software platform (SaaS), the Amdocs Entitlement Server is designed to deliver the scale and reliability required by large telecom operators. Its modular architecture and automated cloud management enable it to scale on demand, introduce updates without service interruptions, and quickly launch new services. The platform supports the full range of entitlement capabilities - from eSIM activation and device pairing to advanced messaging (RCS), voice services over LTE and Wi-Fi (VoLTE/VoWiFi), 5G network capabilities, and emerging satellite connectivity - all within a single, proven platform used by operators worldwide. The Entitlement Server leverages the latest technology from the Amdocs aOS Cognitive Core, ensuring efficient scale and seamless operations.

Key benchmark highlights include:

Active-active deployment across three Azure regions, helping to ensure continuous service with no failover disruption

99.999% availability, meeting Tier-1 operator requirements for mission-critical services

Validation against Azure's Well-Architected Framework for reliability, security, and performance

"This achievement reinforces our commitment to delivering proven, carrier-grade platforms for the world's largest operators," said Anthony Goonetilleke, Group President of Technology and Head of Strategy, Amdocs. "The Entitlement Server brings the same cloud-native and AI-enabled foundations that span our portfolio, capitalizing on Amdocs aOS and Cognitive Core capabilities. "Together with Microsoft, we are enabling service providers to scale confidently and support the next wave of digital services."

"This benchmark demonstrates what becomes possible when carrier-grade telecom workloads are architected for the hyperscale cloud from the ground up," said Igal Figlin, Corporate Vice President - Azure Compute at Microsoft. "By engineering the Amdocs Entitlement Server to the standards of our Well-Architected Framework across three active Azure regions, we've proven that the most demanding telco operations can run with the same resilience and elasticity that the world's largest digital enterprises expect."

Supporting Resources

Learn more about Amdocs eSIM on Microsoft Marketplace, here

Keep up with Amdocs news by visiting the company's website

Follow us on X, Facebook, LinkedIn, and YouTube

About Amdocs

Amdocs helps the world's leading communications and media companies deliver exceptional customer experiences through reliable, efficient, and secure operations at scale. We provide software products and services that embed intelligence into how work runs across business, IT, and network domains - delivering measurable outcomes in customer experience, network performance, cloud modernization, and revenue growth. With our talented people, and more than 40 years of experience running mission-critical systems around the globe, Amdocs runs billions of transactions daily. Our technology is relied on every day, connecting people worldwide and advancing a more inclusive, connected world. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ:DOX) and reported revenue of $4.53 billion in fiscal 2025. For more information, visit www.amdocs.com.

Amdocs' Forward-Looking Statement

This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025, and for the first quarter of fiscal 2026 on February 17, 2026.

Media Contacts

Mario Hajiloizi
Amdocs Public Relations
E-mail: [email protected]

SOURCE: Amdocs Management Limited

Amdocs (DOX - Free Report) came out with quarterly earnings of $1.78 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $1.78 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +0.85%. A quarter ago, it was expected that this provider of computer systems integration would post earnings of $1.75 per share when it actually produced earnings of $1.81, delivering a surprise of +3.43%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Amdocs, which belongs to the Zacks Computers - IT Services industry, posted revenues of $1.17 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.44%. This compares to year-ago revenues of $1.13 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Amdocs shares have lost about 22.6% since the beginning of the year versus the S&P 500's gain of 8.1%.

What's Next for Amdocs?While Amdocs has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Amdocs was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.88 on $1.18 billion in revenues for the coming quarter and $7.44 on $4.7 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Computers - IT Services is currently in the bottom 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Endava PLC Sponsored ADR (DAVA - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 21.

This company is expected to post quarterly earnings of $0.27 per share in its upcoming report, which represents a year-over-year change of -37.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Endava PLC Sponsored ADR's revenues are expected to be $249.69 million, up 1.8% from the year-ago quarter.

Amdocs Limited (DOX) Q2 2026 Earnings Call Transcript

Analysis of 180,000 Patients Validates Measurement-Informed Care for Anxiety and Depression

, /PRNewswire/ -- LifeStance Health, one of the nation's largest providers of outpatient mental health care, published new clinical outcomes data demonstrating that LifeStance patients treated for anxiety and depression broadly experienced clinically significant improvements in their symptoms.

The analysis included nearly 180,000 patients who initiated care between September 2024 and December 2025 across the 33 states LifeStance serves. Key findings include:

Anxiety improvement: 79% of LifeStance patients showed clinically significant improvements in symptoms of anxiety* Depression improvement: 73% of LifeStance patients showed clinically significant improvements in symptoms of depression* Results were consistent across all U.S. geographic regions *Among 140,000 individuals with at least moderate anxiety and 150,000 individuals with at least moderate depression.

Patients were evaluated using two widely used mental health screening tools: the GAD-7 for anxiety and the PHQ-9 for depression. Through LifeStance's measurement‑informed care model, patients complete GAD‑7 and PHQ‑9 assessments at regular intervals, allowing clinicians to track progress over time and adjust care as needed.

LifeStance is committed to clinical excellence and delivering high-quality care. Its model is designed to support improved patient outcomes, including in-person and telehealth options to expand access and support patient engagement; integrated therapy and medication management for more comprehensive and personalized care; and measurement-informed practices that allow clinicians to track and adjust treatment over time.

"For too long, patients seeking mental health care have not had the same clear way to track progress that exists in other areas of medicine, like a blood pressure reading or an A1C result," said Dr. Stephanie Eken, Chief Medical Officer, LifeStance. "Measurement-informed care is changing that dynamic. Our data shows that when patients receive high-quality mental health care, they get better—and LifeStance is demonstrating that at scale."

The full anxiety and depression treatment outcomes analysis is available at LifeStance.com.

About LifeStance
Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation's largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance and its supported practices employ approximately 8,000 psychiatrists, advanced practice nurses, psychologists and therapists and operate across 33 states and more than 550 centers.

Contacts:
Media relations: [email protected]
Investor relations: [email protected]

SOURCE LifeStance Health

Also from this source

Posted by Defense World Staff on Apr 27th, 2026

Chemed (NYSE:CHE – Get Free Report) and LifeStance Health Group (NASDAQ:LFST – Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Institutional & Insider Ownership 95.9% of Chemed shares are held by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are held by institutional investors. 3.3% of Chemed shares are held by insiders. Comparatively, 6.6% of LifeStance Health Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations This is a summary of current ratings and target prices for Chemed and LifeStance Health Group, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemed 2 2 2 0 2.00 LifeStance Health Group 0 2 6 1 2.89 Chemed currently has a consensus target price of $498.00, suggesting a potential upside of 18.38%. LifeStance Health Group has a consensus target price of $9.83, suggesting a potential upside of 39.48%. Given LifeStance Health Group’s stronger consensus rating and higher possible upside, analysts clearly believe LifeStance Health Group is more favorable than Chemed.

Earnings & Valuation This table compares Chemed and LifeStance Health Group”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53 billion 2.43 $265.24 million $18.35 22.92 LifeStance Health Group $1.42 billion 1.92 $9.66 million $0.02 352.50 Chemed has higher revenue and earnings than LifeStance Health Group. Chemed is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk Chemed has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, LifeStance Health Group has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.

Profitability This table compares Chemed and LifeStance Health Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Chemed 10.23% 27.18% 17.38% LifeStance Health Group 0.68% 0.65% 0.45% Summary Chemed beats LifeStance Health Group on 8 of the 15 factors compared between the two stocks.

About Chemed (Get Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

About LifeStance Health Group (Get Free Report)

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINELondon Stock Exchange Group plc – Unsponsored ADR (OTCMKTS:LNSTY) Receives Average Recommendation of “Buy” from Analysts

NEXT HEADLINE »Speed Commerce (OTCMKTS:SPDC) versus A2Z Cust2Mate Solutions (NASDAQ:AZ) Head to Head Comparison

Director Robert Bessler reported the sale of 69,899 shares of LifeStance Health Group (LFST 0.81%) in multiple open-market transactions valued at approximately $492,000, according to the SEC Form 4 filing.

Transaction summaryMetricValueShares sold (indirect)69,899Transaction value~$492KPost-transaction shares (direct)57,619Post-transaction shares (indirect)2,702,057Post-transaction value (direct ownership)~$406KTransaction and post-transaction values based on SEC Form 4 weighted average sell price of $7.04 on April 24, 2026.

Key questionsHow does this sale compare to Bessler's historical transaction size and cadence?
This transaction aligns with Bessler's historical average sell-only trade size of approximately 53,600 shares, and follows a recent series of disposals that have meaningfully reduced his available share capacity.What proportion of Bessler's total position was affected, and what remains?
The sale represented 2.47% of his total holdings, leaving him with 57,619 shares directly and 2.7 million shares indirectly.Were any direct holdings impacted by this transaction?
No direct shares were sold; all activity was executed through indirect holdings.Is this transaction likely to alter Bessler's influence or alignment with shareholders?
Given the small percentage of overall holdings sold, and the substantial remaining indirect position, Bessler retains a meaningful economic interest in LifeStance Health Group.Company overviewMetricValueEmployees7,535Revenue (TTM)$1.42 billionNet income (TTM)$9.66 million1-year price change8.60%* 1-year price change calculated using April 24, 2026 as the reference date.

Company snapshotLifeStance Health Group provides outpatient mental health services, including psychiatric evaluations, psychological and neuropsychological testing, and individual, family, and group therapy, both virtually and in-person across 32 states.It operates a hybrid care delivery model combining physical centers and a digital platform, generating revenue through direct patient services.The company serves a broad demographic, including children, adolescents, adults, and geriatrics seeking mental health care.LifeStance Health Group provides outpatient mental health services in the United States, leveraging a blend of in-person and virtual care. The company’s expansive network and technology-enabled platform enable access to behavioral health services for diverse patient populations.

What this transaction means for investorsBoard of Directors member Dr. Robert Bessler’s sale of LifeStance stock on April 23 and 24 is not a cause for concern for investors. He retained over 2.7 million indirectly-held as well as nearly 60,000 directly-held  shares after the transaction, indicating he is maintaining a sizable equity stake in the company.

The sale came at a time when LifeStance stock was soaring. Shares reached a 52-week high of $8.09 in February. The stock is up thanks to strong business performance.

LifeStance ended 2025 with full year revenue of $1.4 billion, representing a 14% year-over-year increase. The company also made a dramatic turnaround in its bottom line, delivering net income of $9.7 million in 2025 compared to a net loss of $57.4 million in 2024.

As a result of its share price jump, LifeStance Health’s forward price-to-sales ratio of two is elevated, making it a good time to sell. The company expects 2026 revenue to come in around $1.6 billion, showing that its business continues to grow. So while the forward sales multiple is up, now may still be an opportunity to buy as well.

Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the first quarter ended March 31, 2026.

(All results compared to prior-year comparative period, unless otherwise noted)

2026 Highlights and FY 2026 Outlook

Revenue of $403.5 million increased 21% compared to revenue of $333.0 millionClinician base increased 11% to 8,349 clinicians, a sequential net increase of 309 in the first quarterFirst quarter visit volumes increased 18% to 2.5 millionNet income of $14.2 million compared to net income of $0.7 millionAdjusted EBITDA of $51.1 million compared to Adjusted EBITDA of $34.6 millionNet cash provided by operations of $33.1 million in the first quarterFree Cash Flow generation of $22.3 million in the first quarterFor full year 2026, raising revenue expectations to $1.640 billion to $1.680 billion, Center Margin expectations to $547 million to $571 million, and Adjusted EBITDA of $200 million to $220 million “We delivered an exceptional quarter to begin the year, highlighted by strong revenue growth of 21%, net income growth of $13.5 million, and Adjusted EBITDA growth of 48%,” said Dave Bourdon, CEO of LifeStance. “Our performance demonstrates that our differentiated model is meeting the societal trend of growing demand for mental healthcare. We also took an important step forward in our commitment to clinical excellence by announcing an outcomes study on approximately 180,000 LifeStance patients that showed roughly three quarters reported clinically significant improvement in anxiety and depression.”

          Financial Highlights           Q1 2026  Q1 2025  Y/Y (in millions)         Total revenue $403.5  $333.0   21%Income from operations  22.3   1.6  NM Center Margin  135.9   109.8   24%Net income  14.2   0.7  NM Adjusted EBITDA  51.1   34.6   48%As % of Total revenue:         Income from operations  5.5%  0.5%   Center Margin  33.7%  33.0%   Net income  3.5%  0.2%   Adjusted EBITDA  12.7%  10.4%               NM - not meaningful                        (All results compared to prior-year period, unless otherwise noted)

Revenue grew 21% to $403.5 million. Revenue growth in the first quarter was driven primarily by higher visit volumes from net clinician growth, improved clinician productivity, and higher total revenue per visit.Income from operations was $22.3 million and net income was $14.2 million.Center Margin grew 24% to $135.9 million, or 33.7% of total revenue.Adjusted EBITDA increased 48% to $51.1 million, or 12.7% of total revenue. Adjusted EBITDA as a percentage of revenue increased in the first quarter as a result of higher total revenue per visit, lower center costs as a percentage of revenue, and improved operating leverage from revenue growing faster than general and administrative expenses. Balance Sheet, Cash Flow, and Capital Allocation

For the three months ended March 31, 2026, LifeStance generated $33.1 million cash flow from operations. The Company ended the first quarter with cash of $194.8 million and net long-term debt of $262.5 million.

2026 Guidance

LifeStance is providing the following outlook for 2026:

The Company is raising full year revenue to $1.640 billion to $1.680 billion, Center Margin to $547 million to $571 million, and Adjusted EBITDA to $200 million to $220 million.For the second quarter of 2026, the Company expects total revenue of $405 million to $425 million, Center Margin of $135 million to $147 million, and Adjusted EBITDA of $50 million to $60 million. Conference Call, Webcast Information, and Presentations

LifeStance will hold a conference call today, May 7, 2026 at 8:30 a.m. Eastern Time to discuss the first quarter 2026 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 8795477 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.

About LifeStance Health Group, Inc.

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance and its supported practices employ over 8,300 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com.

We routinely post information that may be important to investors on the “Investor Relations” section of our website at investor.lifestance.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Forward-Looking Statements

Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. These statements include, but are not limited to, statements with respect to: full year and second quarter guidance and management's related assumptions; business plans and objectives; our share repurchase authorization and repurchases thereunder; and other statements contained in this press release that are not historical facts. When used in this press release and on the related teleconference, words such as “may,” “will,” “should,” “could,” “intend,” “potential,” “continue,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “target,” “predict,” “project,” “seek” and similar expressions as they relate to us are intended to identify forward-looking statements. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be materially harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide healthcare services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business and financial performance would be harmed; the impact on us of healthcare reform legislation and other changes in the healthcare industry and in healthcare spending is currently unknown, but may harm our business; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the Securities and Exchange Commission. LifeStance does not undertake to update any forward-looking statements made in this press release to reflect any change in management's expectations or any change in the assumptions or circumstances on which such statements are based, except as otherwise required by law.

Non-GAAP Financial Information

This press release contains certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, and Adjusted EBITDA margin. Tables showing the reconciliation of these non-GAAP financial measures to the comparable GAAP measures are included at the end of this release. Management believes these non-GAAP financial measures are useful in evaluating the Company’s operating performance, and may be helpful to securities analysts, institutional investors and other interested parties in understanding the Company’s operating performance and prospects. This press release also refers to Free Cash Flow, which is calculated as net cash provided by (used in) operating activities less purchases of property and equipment. Management believes Free Cash Flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash generated from our operations that, after investments in property and equipment, can be used for future growth. These non-GAAP financial measures, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. Therefore, the Company’s non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net income or income from operations.

Center Margin and Adjusted EBITDA anticipated for the second quarter of 2026 and full year 2026 are calculated in a manner consistent with the historical presentation of these measures at the end of this release. Reconciliation for the forward-looking second quarter of 2026 and full year 2026 Center Margin, Adjusted EBITDA guidance and Free Cash Flow is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. As such, LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.

Management acknowledges that there are many items that impact a company’s reported results and the adjustments reflected in these non-GAAP measures are not intended to present all items that may have impacted these results.

Consolidated Financial Information and Reconciliations

 CONSOLIDATED BALANCE SHEETS
(unaudited)
(In thousands, except for par value)
   March 31, 2026  December 31, 2025 CURRENT ASSETS      Cash and cash equivalents $194,797  $248,642 Patient accounts receivable, net  122,916   95,710 Prepaid expenses and other current assets  38,198   71,848 Total current assets  355,911   416,200 NONCURRENT ASSETS      Property and equipment, net  161,468   161,583 Right-of-use assets  151,526   149,720 Intangible assets, net  175,141   177,665 Goodwill  1,296,999   1,293,346 Other noncurrent assets  4,837   5,419 Total noncurrent assets  1,789,971   1,787,733 Total assets $2,145,882  $2,203,933 LIABILITIES AND STOCKHOLDERS' EQUITY      CURRENT LIABILITIES      Accounts payable $4,292  $6,122 Accrued payroll expenses  117,306   143,327 Other accrued expenses  52,408   42,187 Operating lease liabilities, current  47,369   45,544 Other current liabilities  18,357   14,782 Total current liabilities  239,732   251,962 NONCURRENT LIABILITIES      Long-term debt, net  262,459   265,927 Operating lease liabilities, noncurrent  148,821   148,553 Deferred tax liability, net  16,408   16,408 Other noncurrent liabilities  1,046   68 Total noncurrent liabilities  428,734   430,956 Total liabilities $668,466  $682,918 COMMITMENTS AND CONTINGENCIES      STOCKHOLDERS’ EQUITY      Preferred stock – par value $0.01 per share; 25,000 shares authorized as of
March 31, 2026 and December 31, 2025; 0 shares issued and outstanding as
of March 31, 2026 and December 31, 2025  —   — Common stock – par value $0.01 per share; 800,000 shares authorized as of
March 31, 2026 and December 31, 2025; 387,813 and 388,318 shares
issued and outstanding as of March 31, 2026 and December 31, 2025,
respectively  3,878   3,883 Additional paid-in capital  2,267,921   2,325,758 Accumulated deficit  (794,383)  (808,626)Total stockholders' equity  1,477,416   1,521,015 Total liabilities and stockholders’ equity $2,145,882  $2,203,933            CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(unaudited)
(In thousands, except per share amounts)
   Three Months Ended March 31,   2026  2025 TOTAL REVENUE $403,476  $332,970 OPERATING EXPENSES      Center costs, excluding depreciation and
amortization shown separately below  267,544   223,179 General and administrative expenses  100,330   94,431 Depreciation and amortization  13,318   13,756 Total operating expenses $381,192  $331,366 INCOME FROM OPERATIONS $22,284  $1,604 OTHER EXPENSE      Loss on remeasurement of contingent consideration  (5)  — Transaction costs  (544)  — Interest expense, net  (1,793)  (3,073)Other expense  (182)  (1)Total other expense $(2,524) $(3,074)INCOME (LOSS) BEFORE INCOME TAXES  19,760   (1,470)INCOME TAX (PROVISION) BENEFIT  (5,517)  2,179 NET INCOME $14,243  $709 EARNINGS PER SHARE      Basic  0.04   0.00 Diluted  0.04   0.00 Weighted-average shares outstanding      Basic  387,264   383,272 Diluted  395,084   390,666        NET INCOME $14,243  $709 OTHER COMPREHENSIVE LOSS      Unrealized losses on cash flow hedge, net of tax  —   (317)COMPREHENSIVE INCOME $14,243  $392            CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands)
   Three Months Ended March 31,   2026  2025 CASH FLOWS FROM OPERATING ACTIVITIES      Net income $14,243  $709 Adjustments to reconcile net income to net cash provided by
(used in) operating activities:      Depreciation and amortization  13,318   13,756 Non-cash operating lease costs  10,717   10,231 Stock-based compensation  15,201   18,584 Amortization of discount and debt issue costs  251   251 Other, net  129   357 Change in operating assets and liabilities, net of businesses acquired:      Patient accounts receivable, net  (26,953)  (8,568)Prepaid expenses and other current assets  33,779   (4,515)Accounts payable  (1,017)  (77)Accrued payroll expenses  (26,362)  (17,540)Operating lease liabilities  (9,955)  (11,894)Other accrued expenses  9,758   (4,386)Net cash provided by (used in) operating activities $33,109  $(3,092)CASH FLOWS FROM INVESTING ACTIVITIES      Purchases of property and equipment  (10,767)  (7,168)Acquisitions of businesses, net of cash acquired  (3,144)  — Net cash used in investing activities $(13,911) $(7,168)CASH FLOWS FROM FINANCING ACTIVITIES      Payments of long-term debt  —   (1,813)Taxes related to net share settlement of equity awards  (23,936)  (8,162)Repurchases of common stock  (49,107)  — Net cash used in financing activities $(73,043) $(9,975)NET DECREASE IN CASH AND CASH EQUIVALENTS  (53,845)  (20,235)Cash and cash equivalents - beginning of period  248,642   154,571 CASH AND CASH EQUIVALENTS – END OF PERIOD $194,797  $134,336 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION      Cash paid for interest, net $77  $4,382 Cash paid for taxes, net of refunds $349  $609 SUPPLEMENTAL DISCLOSURES OF NON CASH INVESTING AND
FINANCING ACTIVITIES      Contingent consideration incurred in acquisitions of businesses $1,008  $— Acquisition of property and equipment included in liabilities $2,489  $2,348            RECONCILIATION OF INCOME FROM OPERATIONS TO CENTER MARGIN
   Three Months Ended March 31,   2026  2025 (in thousands)      Income from operations $22,284  $1,604 Adjusted for:      Depreciation and amortization  13,318   13,756 General and administrative expenses(1)  100,330   94,431 Center Margin $135,932  $109,791            (1) Represents salaries, wages and employee benefits for our executive leadership, finance, human resources, marketing, billing and credentialing support and technology infrastructure and stock-based compensation for all employees.      RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA
   Three Months Ended March 31,   2026  2025 (in thousands)      Net income $14,243  $709 Adjusted for:      Interest expense, net  1,793   3,073 Depreciation and amortization  13,318   13,756 Income tax provision (benefit)  5,517   (2,179)Loss on remeasurement of contingent consideration  5   — Stock-based compensation expense  15,201   18,584 Loss on disposal of assets  182   1 Transaction costs(1)  544   — Executive transition costs  —   185 Litigation costs(2)  (197)  205 Strategic initiatives(3)  86   — Real estate optimization and restructuring charges(4)  —   (45)Amortization of cloud-based software implementation costs(5)  418   357 Adjusted EBITDA $51,110  $34,646            (1) Primarily includes capital markets advisory, consulting, accounting and legal expenses related to the underwritten public offering of shares of our common stock by certain selling stockholders completed in the first quarter of 2026. (2) Litigation costs, net of insurance recoveries, include only those costs which are considered non-recurring and outside of the ordinary course of business based on the following considerations, which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) the complexity of the case (e.g., complex class action litigation), (iii) the nature of the remedy(ies) sought, including the size of any monetary damages sought, (iv) the counterparty involved, and (v) our overall litigation strategy. During each of the three months ended March 31, 2026 and 2025, litigation costs included cash expenses related to certain litigation matters, including a privacy class action litigation, and for the three months ended March 31, 2025, a compensation model class action litigation. (3) Strategic initiatives consist of expenses directly related to evaluating and implementing a critical enterprise-wide scalable electronic health resources system in connection with our significant expansion. Strategic initiatives represents costs, such as third-party consulting costs and one-time costs, that are not part of our ongoing operations related to this enterprise-wide system. We considered the frequency and scale of this enterprise upgrade when determining that the expenses were not normal, recurring operating expenses. (4) Real estate optimization and restructuring charges consist of cash expenses and non-cash charges related to our real estate optimization initiative, which included certain asset impairment and disposal costs, certain gains and losses related to early lease terminations, and exit and disposal costs related to our real estate optimization initiative to consolidate our physical footprint during 2023. As the decision to close these centers was part of a significant strategic project driven by a historic shift in behavior, the magnitude of center closures was greater than what would be expected as part of ordinary business operations and did not constitute normal recurring operating activities. During the three months ended March 31, 2025, real estate optimization and restructuring charges consisted of certain gains and losses related to early lease terminations of previously abandoned real estate leases in 2023. (5) Represents amortization of capitalized implementation costs related to cloud-based software arrangements that are included within general and administrative expenses included in our unaudited consolidated statements of operations and comprehensive income.

SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced that pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”), certain stockholders of the Company (the “Selling Stockholders”) intend to offer 35,000,000 shares of LifeStance’s common stock, par value $0.01 per share (the “Common Stock”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.

In addition, the Company has authorized the concurrent purchase from the underwriter of 6,000,000 shares of Common Stock (the “Repurchase”), subject to the completion of the offering. The price per share for the shares to be repurchased by the Company will be the same as the price per share payable by the underwriter to the Selling Stockholders. The underwriter will not receive any underwriting fees for the shares being repurchased by the Company. The Repurchase will be subject to completion of the offering and the satisfaction of other customary conditions. The offering is not conditioned upon the completion of the Repurchase.

J.P. Morgan is acting as the underwriter for the offering.

An automatic shelf registration statement (including a prospectus) relating to the offering of Common Stock was filed by LifeStance with the SEC on May 21, 2024 and became effective upon filing. Before you invest, you should read the prospectus in the shelf registration statement and the documents incorporated by reference therein and the prospectus supplement that the Company has filed with the SEC for more complete information about the Company and the offering. The offering will be made only by means of a prospectus and a related prospectus supplement relating to the offering, copies of which may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]. A copy of the prospectus and the related prospectus supplement relating to the offering may also be obtained free of charge by visiting EDGAR on the SEC’s website at www.sec.gov. 

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Nothing herein should be construed as an offer to sell, or the solicitation of an offer to buy, any shares of Common Stock subject to the Repurchase.

About LifeStance

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance and its supported practices employ over 8,300 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.

Forward-Looking Statements

This press release may contain “forward-looking” statements based on the Company’s beliefs and assumptions and on information currently available to the Company. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions, although not all forward-looking statements contain these identifying words. For example, all statements we make regarding the terms of the proposed public offering and the Repurchase are forward-looking statements.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by any forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our growth depends on our ability to recruit, acquire and retain clinicians; we operate in a competitive industry, and if we are not able to compete effectively, our business, results of operations and financial condition would be harmed; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; if we are unable to adapt to healthcare reform legislation and other changes in the healthcare industry and in healthcare spending, our business could be harmed; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the SEC.

For the reasons described above, we caution you against relying on any forward-looking statements, which should be read in conjunction with the other cautionary statements included elsewhere in this press release and risk factors discussed from time to time in the Company’s filings with the SEC, which can be found at the SEC’s website at http://www.sec.gov. Any forward-looking statement in this presentation speaks only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise any forward-looking statement after the date of this press release, whether as a result of new information, future developments or otherwise, except as may be required by law. No recipient should, therefore, rely on these forward-looking statements as representing the views of the Company or its management as of any date subsequent to the date of the press release.

SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced the pricing of a secondary underwritten public offering of 35,000,000 shares of LifeStance’s common stock, par value $0.01 per share (the “Common Stock”) at a public offering price of $8.15 per share, pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) from certain stockholders of the Company (the “Selling Stockholders”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.

In addition, the Company has agreed to purchase from the underwriter 6,000,000 shares of Common Stock to be sold by the Selling Stockholders in the offering, at a price per share equal to the price per share to be paid by the underwriter to the Selling Stockholders (the “Repurchase”). The Repurchase is conditioned upon the completion of the offering and the satisfaction of other customary conditions. The offering is not conditioned upon the completion of the Repurchase. The underwriter will not receive any compensation for the shares of Common Stock being purchased by the Company.

Subject to customary closing conditions, the offering and the Repurchase are expected to settle and close on or about May 12, 2026.

J.P. Morgan is acting as the underwriter for the offering.

An automatic shelf registration statement (including a prospectus) relating to the offering of Common Stock was filed by LifeStance with the SEC on May 21, 2024 and became effective upon filing. Before you invest, you should read the prospectus in the shelf registration statement and the documents incorporated by reference therein and the prospectus supplement that the Company has filed with the SEC for more complete information about the Company and the offering. The offering is being made only by means of a prospectus and a related prospectus supplement relating to the offering, copies of which may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]. A copy of the prospectus and the related prospectus supplement relating to the offering may also be obtained free of charge by visiting EDGAR on the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Nothing herein should be construed as an offer to sell, or the solicitation of an offer to buy, any shares of Common Stock subject to the
Repurchase.

About LifeStance

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance and its supported practices employ over 8,300 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.

Forward-Looking Statements

This press release may contain “forward-looking” statements based on the Company’s beliefs and assumptions and on information currently available to the Company. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions, although not all forward-looking statements contain these identifying words. For example, all statements we make regarding the terms of the proposed public offering and the Repurchase are forward-looking statements.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by any forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our growth depends on our ability to recruit, acquire and retain clinicians; we operate in a competitive industry, and if we are not able to compete effectively, our business, results of operations and financial condition would be harmed; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; if we are unable to adapt to healthcare reform legislation and other changes in the healthcare industry and in healthcare spending, our business could be harmed; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the SEC.

For the reasons described above, we caution you against relying on any forward-looking statements, which should be read in conjunction with the other cautionary statements included elsewhere in this press release and risk factors discussed from time to time in the Company’s filings with the SEC, which can be found at the SEC’s website at http://www.sec.gov. Any forward-looking statement in this presentation speaks only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise any forward-looking statement after the date of this press release, whether as a result of new information, future developments or otherwise, except as may be required by law. No recipient should, therefore, rely on these forward-looking statements as representing the views of the Company or its management as of any date subsequent to the date of the press release.

Shares of LifeStance Health Group (LFST - Free Report) have gained 21.8% over the past four weeks to close the last trading session at $7.93, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10.39 indicates a potential upside of 31%.

The mean estimate comprises nine short-term price targets with a standard deviation of $1.58. While the lowest estimate of $8.00 indicates a 0.9% increase from the current price level, the most optimistic analyst expects the stock to surge 63.9% to reach $13.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.

However, an impressive consensus price target is not the only factor that indicates a potential upside in LFST. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.

Price, Consensus and EPS Surprise

Here's What You Should Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.

While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?

They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.

However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.

That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.

Why LFST Could Witness a Solid UpsideThere has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

The Zacks Consensus Estimate for the current year has increased 26.9% over the past month, as two estimates have gone higher compared to no negative revision.

Moreover, LFST currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Therefore, while the consensus price target may not be a reliable indicator of how much LFST could gain, the direction of price movement it implies does appear to be a good guide.

LifeStance Health Group (LFST - Free Report) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.

The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this outpatient mental health services provider, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For LifeStance Health Group, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsFor the current quarter, the company is expected to earn $0.02 per share, which is a change of +300.0% from the year-ago reported number.

Over the last 30 days, two estimates have moved higher for LifeStance Health compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 40%.

Current-Year Estimate RevisionsFor the full year, the earnings estimate of $0.11 per share represents a change of +450.0% from the year-ago number.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for LifeStance Health. Over the past month, two estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 26.92%.

Favorable Zacks RankThe promising estimate revisions have helped LifeStance Health earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineInvestors have been betting on LifeStance Health because of its solid estimate revisions, as evident from the stock's 21.8% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away.

A downtrend has been apparent in LifeStance Health Group (LFST - Free Report) lately. While the stock has lost 5.3% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.

The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the stock. On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this outpatient mental health services provider enhances its prospects of a trend reversal.

What is a Hammer Chart and How to Trade It?This is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a 'hammer.'

In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price.

When it occurs at the bottom of a downtrend, this pattern signals that the bears might have lost control over the price. And, the success of bulls in stopping the price from falling further indicates a potential trend reversal.

Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors.

Like every technical indicator, the hammer chart pattern has its limitations. Particularly, as the strength of a hammer depends on its placement on the chart, it should always be used in conjunction with other bullish indicators.

Here's What Makes the Trend Reversal More Likely for LFSTAn upward trend in earnings estimate revisions that LFST has been witnessing lately can certainly be considered a bullish indicator on the fundamental side. That's because empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

Over the last 30 days, the consensus EPS estimate for the current year has increased 42.3%. What it means is that the sell-side analysts covering LFST are majorly in agreement that the company will report better earnings than they predicted earlier.

If this is not enough, you should note that LFST currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Moreover, a Zacks Rank of 1 for LifeStance Health is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company's prospects are beginning to improve.

Seneca Foods (NASDAQ: SENEA - Get Free Report) and TreeHouse Foods (NYSE: THS - Get Free Report) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends. Analyst Ratings This is a breakdown

Posted by Defense World Staff on Apr 7th, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) insider Amy Simon sold 6,700 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $24.58, for a total transaction of $164,686.00. Following the transaction, the insider directly owned 102,735 shares of the company’s stock, valued at $2,525,226.30. The trade was a 6.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Beam Therapeutics Stock Down 1.7% Beam Therapeutics stock opened at $24.23 on Tuesday. The firm has a 50-day moving average price of $26.51 and a two-hundred day moving average price of $26.43. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of -23.99 and a beta of 2.18. Beam Therapeutics Inc. has a 52-week low of $13.52 and a 52-week high of $36.44.

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported $2.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $3.46. The firm had revenue of $114.11 million during the quarter, compared to analyst estimates of $13.22 million. Beam Therapeutics had a negative net margin of 57.24% and a negative return on equity of 30.65%. Beam Therapeutics’s revenue was up 280.3% on a year-over-year basis. During the same period in the previous year, the business posted ($1.09) EPS. Research analysts expect that Beam Therapeutics Inc. will post -4.57 earnings per share for the current year.

Institutional Trading of Beam Therapeutics Several institutional investors have recently modified their holdings of the company. Purpose Unlimited Inc. acquired a new stake in shares of Beam Therapeutics in the fourth quarter valued at $80,000. Invesco Ltd. lifted its holdings in shares of Beam Therapeutics by 20.5% in the fourth quarter. Invesco Ltd. now owns 213,185 shares of the company’s stock valued at $5,909,000 after buying an additional 36,321 shares during the period. Axxcess Wealth Management LLC acquired a new stake in shares of Beam Therapeutics in the fourth quarter valued at $212,000. XTX Topco Ltd acquired a new stake in Beam Therapeutics during the fourth quarter valued at approximately $426,000. Finally, Virtus Investment Advisers LLC lifted its stake in Beam Therapeutics by 49.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 9,724 shares of the company’s stock valued at $270,000 after purchasing an additional 3,200 shares during the last quarter. Institutional investors and hedge funds own 99.68% of the company’s stock.

Analysts Set New Price Targets BEAM has been the subject of a number of analyst reports. Sanford C. Bernstein boosted their price target on Beam Therapeutics from $37.00 to $41.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 20th. Citigroup boosted their price target on Beam Therapeutics from $64.00 to $68.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Wedbush boosted their price target on Beam Therapeutics from $57.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. UBS Group began coverage on shares of Beam Therapeutics in a report on Wednesday, January 7th. They issued a “neutral” rating and a $28.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Beam Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $49.36.

Read Our Latest Stock Report on BEAM

Beam Therapeutics Company Profile (Get Free Report)

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.

Recommended Stories Five stocks we like better than Beam Therapeutics

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBeam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares

NEXT HEADLINE »Credo Technology Group (NASDAQ:CRDO) CTO Chi Fung Cheng Sells 2,434 Shares of Stock

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That’s according to Ben Lamm, CEO of Colossal Biosciences.

On episode 245 of the Moonshots with Peter Diamandis podcast, Lamm made the case that gene drive technology is the only scalable, humane answer.

“In New Zealand, in Australia, in parts of Africa, people are killing animals because they’re invasive species. They’re killing cats, they’re killing possums… that’s an animal welfare nightmare.”

Colossal’s proposed solution: genetically modified invasive animals that produce only male offspring, allowing populations to “live out their normal lives” before naturally dying out. No poison, no mass culling. Lamm also emphasized that Colossal’s proprietary gene drive technologies are “safer than what has ever been dispersed in the wild” and, critically, reversible: “we have the ability to roll it back.”

Texas has declared the screwworm a national emergency, with the pest currently spreading from Honduras through Mexico and threatening to “decimate our cattle and bison industry.” Diamandis noted the scale of the commercial opportunity: “dozens of species to be attacked and cost dozens of billions.”

Lamm’s broader point: 99% of synthetic biology and genome engineering talent focuses only on human healthcare, but the same technologies “apply to other use cases I think are even larger economically, but also have a bigger opportunity to help us.” He compared current invasive species control methods to “archaic ways of treating cancer versus what we know is here and what is coming.”

The Publicly Investable Gene-Editing Universe Colossal is private, so the question becomes where this thesis shows up in public markets. The three companies building the foundational CRISPR toolkit are CRISPR Therapeutics (NASDAQ:CRSP | CRSP Price Prediction), Beam Therapeutics (NASDAQ:BEAM), and Intellia Therapeutics (NASDAQ:NTLA).

CRISPR Therapeutics carries a $4.9 billion market cap with 17 analyst buy ratings and a consensus target of $83.35 against a current price of $51.22. Beam sits at $27.43 with 15 buy ratings and a $51.20 analyst target. Intellia, the smallest of the three at a $1.59 billion market cap, has surged 50% year-to-date to $13.49, with Phase 3 data on its lead HAE program expected mid-2026.

Their value here is as platform plays: the delivery systems, base editing precision, and in vivo editing capabilities they are refining for rare diseases are the same building blocks gene drive applications would require. If Lamm’s thesis proves out and gene drives move toward regulatory acceptance, these platforms become the infrastructure layer underneath it.

If gene drives become the standard, the companies that own the most precise, reversible genome editing platforms stand to benefit well beyond their current therapeutic pipelines. That’s the thread I’ll be watching.

As per recent news, Ondas completed its merger with U.S. defense prime contractor Mistral on April 24 in a $175 million deal, adding programs exceeding $1 billion and expanding direct prime participation across U.S. Department of War programs.

Cramer said he likes Halliburton Co (NYSE:HAL) very much as it has been a “good stock even in a bad oil market, so it's been a great stock in a good oil market.”

Lending support to his choice, Halliburton, on April 21, reported better-than-expected first-quarter financial results.

Nokia Oyj (NYSE:NOK) is a “winner,” Cramer said.

Cramer said he is a growth buyer, and Snap (NYSE:SNAP) does not have growth.

The Mad Money host said he likes Cameco Corporation (NYSE:CCJ) because it's a real uranium company.

When asked about Harley-Davidson Inc (NYSE:HOG), he said, “The technology is absolutely terrific, but the actual earnings, they're just blah. I can't go for it.”

Price Action:

Photo: katz / Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half of 2026 Data from Phase 1/2 BEACON Clinical Trial of Risto-cel in Sickle Cell Disease Published in April 1 Issue of the New England Journal of Medicine; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Investigational New Drug (IND) Application for BEAM-304 in PKU and Data from BEAM-301 in GSDIa Anticipated in 2026 Ended First Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into mid-2029 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) --   Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2026 financial results and provided updates across the company's hematology and genetic disease franchises.

Key Takeaways Beam Therapeutics posted Q1 revenues of $31.7M, topping estimates as collaboration revenues increased.BEAM plans a 2026 BLA filing for risto-cel after updated SCD study data showed progress.BEAM-302 showed durable AAT increases in AATD, with pivotal cohort enrollment set for 2H'26. Beam Therapeutics (BEAM - Free Report) incurred a loss of 91 cents per share in the first quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 87 cents. The company had reported a loss of $1.23 per share in the year-ago quarter.

Revenues totaled $31.7 million, beating the Zacks Consensus Estimate of $21 million. The company had recorded revenues of $7.4 million in the year-ago quarter. The top line primarily comprises license and collaboration revenues.

Year to date, shares of Beam Therapeutics have risen 13.5% against the industry’s 0.2% decline.

Image Source: Zacks Investment Research

BEAM's Q1 Results in DetailResearch and development expenses were $104.5 million in the first quarter, up 5.8% from the year-ago quarter.

General and administrative expenses surged 23.2% year over year to $34.4 million.

As of March 31, 2026, Beam Therapeutics had cash, cash equivalents and marketable securities worth $1.21 billion compared with $1.25 billion as of Dec. 31, 2025. The company expects its cash position, including the initial $100 million received and an anticipated additional $100 million from its financing agreement with Sixth Street, to support operations into mid-2029.

BEAM's Pipeline UpdatesBeam Therapeutics is developing its leading ex-vivo genome-editing candidate, risto-cel, in the phase I/II BEACON study for the treatment of patients with SCD, an inherited blood disorder.

The company presented updated data from the BEACON study in December 2025, which continued to show evidence of risto-cel’s differentiated treatment profile in SCD patients. BEAM plans to submit a biologics licensing application (BLA) for risto-cel by the end of 2026.

Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for the treatment of glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD), respectively.

BEAM-301 is being evaluated in a phase I/IIdose-exploration study in patients with GSDIa. Initial data from the study are expected in 2026.

The company is developing BEAM-302 in an ongoing phase I/II dose-escalation study for the treatment of AATD. In March, BEAM announced positive updated data from the study showing that BEAM-302 produced durable increases in functional AAT levels, significant reductions in mutant Z-AAT and generation of corrected M-AAT with a favorable safety profile across single doses up to 75 mg.

Following the FDA feedback, Beam Therapeutics aims to pursue an accelerated approval pathway for BEAM-302 and plans to initiate a global pivotal expansion cohort in the second half of 2026. The study is expected to enroll around 50 additional patients with AATD-related lung disease to support a future BLA filing.

Dosing in the ongoing phase I healthy volunteer study, evaluating BEAM-103, an anti-CD117 monoclonal antibody for the treatment of SCD, is expected to be completed in the first half of 2026.

The company expanded its liver-targeted genetic disease franchise with BEAM-304 for the treatment of phenylketonuria and plans to file an investigational new drug application with the FDA in 2026.

BEAM’s Zacks Rank & Stocks to ConsiderBeam Therapeutics currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the biotech sector are Amarin Corporation (AMRN - Free Report) , Indivior Pharmaceuticals (INDV - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $7.01 to $6.36. Over the same period, loss per share estimates for 2027 have also narrowed from $5.50 to $4.64. AMRN shares have risen 5.9% year to date.

Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 50.02%.

Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.03 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.46. INDV shares have risen 10.4% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have declined from $2.14 to $1.75. Over the same period, EPS estimates for 2027 have decreased from $3.79 to $2.91. LQDA shares have gained 22.6% year to date.

Liquidia’s earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining occasions, with the average surprise being 39.38%.

May 13, 2026 07:00 ET  | Source: Beam Therapeutics

CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 2026 RBC Capital Markets Healthcare Conference on Wednesday, May 20, 2026, at 10:30 a.m. ET in New York.

The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contact:

Holly Manning
Beam Therapeutics
[email protected]

The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.

, /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation (A1F), today announced Beam Therapeutics as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines.

Beam Therapeutics AlphaDetect is dedicated to identifying everyone at risk for this progressive, irreversible genetic condition by elevating awareness and removing barriers to detection. The organization will provide free genetic testing for alpha-1 in their proprietary laboratory, at no cost to insurance or patients. In addition, they provide support from a committed engagement team for healthcare providers. These efforts will increase the availability of Alpha-1 detection tools and support at the practice level while also partnering with healthcare providers to strategically advance protocols and technologies across healthcare systems.

"Advancing Alpha-1 detection requires a focused effort," said Amy Simon, MD, Chief Medical Officer of Beam Therapeutics. "Working with the Alpha-1 Foundation, and now AlphaDetect as a subsidiary of A1F, there is an opportunity to accelerate detection across the Alpha-1 community aligned with clinical guidelines. These efforts will help bring much needed answers to patients and their families. As one of the inaugural sponsors of this effort, we're proud to have closely collaborated with AlphaDetect on this shared goal of increasing awareness and testing for Alpha-1."

"Alpha-1 is a progressive, genetic lung and liver condition where delays in detection may have real, irreversible consequences," said Julie Murray, CEO of AlphaDetect. "The ability to scale proven approaches to identifying at-risk patients, quickly and systematically, can inform timely decisions for those impacted. The support and commitment from Beam Therapeutics are important and appreciated as we continue to advance Alpha-1 detection."

Alpha-1 remains significantly underdiagnosed, with more than 90% of affected individuals estimated to be unidentified. It is also the leading known genetic risk factor for COPD and is associated with liver disease in both children and adults. Importantly, detection also provides a point of entry into the Alpha-1 community, opening the door to the comprehensive information, support, and resources needed for the journey ahead.

"This support builds on Beam Therapeutic's commitment to progressive clinical research to support the Alpha-1 community and represents an important step forward in how we approach detection," said Scott Santarella, CEO of the Alpha-1 Foundation. "By expanding these efforts through AlphaDetect, we can identify more individuals earlier and deliver on A1F's mission of improving their lives."

The latest clinical guidelines recommend testing for Alpha-1 in all individuals with COPD, treatment-resistant asthma, or unexplained liver disease. Yet real-world results fall far short of this. AlphaDetect is committed to closing the gap. Beam Therapeutics sponsorship and commitment will help AlphaDetect scale efforts to enhance provider education, broaden detection strategies, and work across the Alpha-1 community to identify individuals with Alpha-1.

About AlphaDetect 

AlphaDetect, founded in 2025, accelerates detection to uncover everyone genetically at risk for Alpha-1. Located in Durham, NC, AlphaDetect will operate as a limited liability company and a non-profit subsidiary of Alpha-1 Foundation, holding tax-exempt status under Section 501(c)3 of the Internal Revenue Code. 

For more information, visit https://alpha1.org/alphadetect/

Contact: Cindy Machles

917-453-9760

Email: [email protected]

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.

For more information, visit beamtx.com

Contact: Holly Manning

Vice President, Investor Relations and External Communications

857-327-9449

[email protected]

About the Alpha-1 Foundation

The Alpha-1 Foundation, founded in 1995, is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by the condition worldwide. A1F has invested over $100 million to support Alpha-1 research and programs at 130 institutions in North America, Europe, the Middle East and Australia.

For more information, visit alpha1.org

Contact: Jeanne Kushner

Senior Director of Communications & Policy

877-228-7321

[email protected] 

SOURCE Alpha-1 Foundation

On May 15, 2026, ADAR1 Capital Management disclosed a new position in Beam Therapeutics (BEAM +2.79%), acquiring 1,446,375 shares in an estimated $40.13 million trade based on quarterly average pricing.

What happenedAccording to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, ADAR1 Capital Management, opened a new position in Beam Therapeutics, buying 1,446,375 shares. The estimated transaction value, based on the average closing price for the January–March 2026 quarter, was $40.13 million. At quarter end, the position was valued at $34.47 million, reflecting both the purchase and price changes.

What else to knowThis was a new position for the fund, making up 2.03% of 13F reportable assets as of March 31, 2026.Top five holdings after the filing:NASDAQ: ABVX: $155.22 million (9.4% of AUM)NASDAQ: PTGX: $104.78 million (6.4% of AUM)NASDAQ: ROIV: $91.02 million (5.5% of AUM)NASDAQ: IMVT: $66.55 million (4.0% of AUM)NYSEMKT: SPY: $49.39 million (3.0% of AUM)As of May 15, 2026, Beam Therapeutics shares were priced at $27.93, up 61.9% over the past year, outperforming the S&P 500 by 36.7 percentage points.Company overviewMetricValuePrice (as of market close May 15, 2026)$27.93Market Capitalization$2.87 billionRevenue (TTM)$164.01 millionNet Income (TTM)($65.04 million)Company snapshotDevelops precision genetic medicines targeting serious diseases, with lead candidates addressing sickle cell disease, beta thalassemia, T-cell acute lymphoblastic leukemia, and glycogen storage disorders.Operates a biotechnology business model focused on research, development, and commercialization of gene-editing therapies, generating revenue through product development, strategic collaborations, and licensing agreements.Serves patients with severe genetic and rare diseases, partnering with healthcare providers, research institutions, and pharmaceutical companies in the United States and globally.Beam Therapeutics is a biotechnology company specializing in precision genetic medicines, leveraging base editing technology to address a range of serious genetic disorders. The company advances a diversified pipeline through both proprietary research and strategic collaborations with leading academic and industry partners. With a focus on innovation and targeted therapies, Beam Therapeutics aims to establish a competitive position in the rapidly evolving field of gene editing.

Today's Change

(

2.79

%) $

0.82

Current Price

$

30.23

What this transaction means for investorsInvesting in pre-commercial gene therapy means betting on science that hasn't reached patients yet. You're wagering the technology works, clinical trials succeed, and the FDA approves before the cash runs out. ADAR1 Capital Management made that bet with a $40 million Beam Therapeutics position in Q1.

Beam develops gene-editing therapies for rare diseases but has no approved drugs yet. It has $1.2 billion in cash and burns around $140 million quarterly on R&D. Revenue comes entirely from collaboration milestone payments, not product sales.

The company expects to file for FDA approval of risto-cel (a sickle cell treatment) by late 2026 and will start pivotal trials for BEAM-302 (treating a rare genetic liver disease) in the second half of 2026. Both programs have shown promising early data and potential accelerated approval pathways.

For average investors, this is speculative biotech investing. The upside is significant if one or both drugs get approved and gain market traction. The risk is clinical trial failures, regulatory setbacks, or manufacturing issues derailing the pathway to profitability. Gene therapy is high-reward science with high execution risk.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics. The Motley Fool recommends Protagonist Therapeutics and Roivant Sciences. The Motley Fool has a disclosure policy.

3 Biotech Stocks That Could Benefit from the Patent CliffBeam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year.

Speaking at RBC Capital Markets’ Global Healthcare Conference in a discussion with Senior Biotechnology Research Analyst Luca Issi, Evans described Beam as a “next-generation gene-editing company” focused on base editing, a form of CRISPR designed to make permanent single-letter changes in genes without creating a double-strand break.

Get Beam Therapeutics alerts:

MarketBeat Week in Review – 3/4 – 3/8Evans said that distinction could allow Beam to make “more therapeutic edits” and “more precise edits,” including correcting mutations back to normal rather than only knocking genes out.

Alpha-1 Program Shows Dose Selection Progress A major focus of the discussion was BEAM-302, Beam’s program for alpha-1 antitrypsin deficiency. Evans said the program is designed to correct the single-letter misspelling in the alpha-1 gene back to normal, which he said is the first time anyone has been able to do so.

Beam Therapeutics Bolts Higher on Gene Therapy Licensing PaymentsEvans said earlier data showed that a 60-milligram dose achieved alpha-1 levels above 11 micromolar, a threshold he described as important because carriers who do not have the disease generally live above that line, while patients with progressive lung and liver damage are usually below it.

According to Evans, additional dose exploration around 60 milligrams, including a 75-milligram dose and a two-dose 60-milligram regimen, did not produce meaningful additional pharmacodynamic benefit. He said the results confirmed that 60 milligrams is the dose Beam wants to use.

Evans said the larger data set showed the 60-milligram dose produced an average alpha-1 level of 16 micromolar, with normal M protein levels above 90% and Z protein reduced by 84%.

“We had clearly and dramatically changed the disease physiology to at least a carrier physiology,” Evans said, adding that this supports Beam’s view that treated patients should not experience progressive disease going forward.

Safety and Redosing Discussed Issi asked about tolerability of a second 60-milligram dose, which Evans said was not as well tolerated as the first. Evans said it was difficult to know why, noting that preclinical data suggested eight weeks should have been enough time for the first lipid nanoparticle dose to clear. However, he said alpha-1 livers may differ in physiology and macrophage biology, potentially retaining some sensitivity.

Evans characterized the observed events as manageable. He said Beam saw higher infusion-related reactions, such as grade two events treated with Motrin, and one patient with a grade three AST/ALT elevation that was asymptomatic, did not require hospitalization, did not involve bilirubin changes and resolved quickly.

Evans said he did not believe the findings indicate that lipid nanoparticle redosing is not possible. He noted that Beam still plans to redose patients who previously received subtherapeutic 15-milligram and 30-milligram doses with the selected 60-milligram dose.

On liver enzyme elevations, Evans said the pattern Beam observed was consistent with a “classic LNP signal,” in which liver enzymes rise quickly and then fall quickly. He said the key safety considerations are rapid improvement within days and no bilirubin change, which he said Beam observed.

Bystander Editing and Protein Function Evans also addressed investor questions about bystander editing. He said BEAM-302 can create a mixture of corrected M protein and an M variant, a result Beam has known about and characterized over time.

Evans said Beam has shown that the variant is secreted normally, is functional and has a structure comparable to normal M protein. He also said the variant position is commonly varied in the human population and that the specific variant Beam creates is found in people and is not associated with disease.

He pointed to functional data showing direct inhibition of human neutrophil elastase using serum from treated patients, which he said demonstrated that the protein mixture created by the therapy is functional.

Regulatory Path and Liver Endpoints Evans said Beam has alignment with the FDA on an accelerated approval path for BEAM-302, describing it as a “classic accelerated approval” strategy rather than one reliant on newer regulatory mechanisms. He said the company is working with stable FDA review teams and that the agency’s main request was for 12 months of follow-up because alpha-1 levels can vary over time.

Evans said Beam plans to enroll 50 patients and follow them for one year before submitting the data. He said the biomarker package includes total alpha-1 levels, M protein levels, percentage of M protein, reduction in Z protein, protein functionality and inducibility.

On liver benefit, Evans said Beam believes BEAM-302 could help both lung and liver manifestations of alpha-1 antitrypsin deficiency by raising functional alpha-1 and lowering Z protein. He said Beam is conducting biopsies in Part B patients before treatment and at six and 12 months to assess whether aggregates resolve and whether fibrosis changes over time.

Evans said the Part B patients, who have more advanced liver disease, have so far tolerated the drug similarly to Part A patients, supporting an all-comer Cohort C.

Sickle Cell Program and Pricing Outlook Evans said Beam’s ex vivo sickle cell disease program, risto-cel, could have a BLA filing as early as the end of this year. He said Beam believes it has a strong manufacturing process, with a vein-to-vein time of just over four months, which he said could allow patients to be treated quickly and predictably.

Evans said risto-cel is aimed at severe sickle cell patients who may be candidates for a transplant-based option, while Beam also continues to work on in vivo approaches that could reach a broader sickle cell population over time.

On pricing, Evans said Beam would price a one-time alpha-1 therapy higher than one year of augmentation therapy, but said payers are sophisticated and evaluate long-term pharmacoeconomic value. He cited sickle cell disease as an example where high lifetime costs have supported genetic medicine pricing, while noting that it is too early to discuss specific pricing for alpha-1.

Evans said Beam believes alpha-1 antitrypsin deficiency has a strong value story because a one-time therapy could potentially address both lung and liver disease.

About Beam Therapeutics NASDAQ: BEAMBeam Therapeutics, Inc NASDAQ: BEAM is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Beam Therapeutics Right Now?Before you consider Beam Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.

While Beam Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report